Pipeline

Our lead candidate for the treatment of GAN we refer to as "earthquake".  We will soon be testing in mechanistically similar disease models that have intermediate filament proteins (IFs) as a hallmark of disease pathology.  Our drug seems to take down the scaffolding IFs adhere to.

We plan to license assays to biosciences companies to further research in the field and provide revenue streams.

We are in the early stages of an ASO program aimed at freeing mRNA from stress granules.  If successful, the impact may be profund for a number of indications.  Seydous et el, Nat Cell Biol., 2019 report that several neurodegenerative diseases have been associated with cytoplasmic aggregates that contain RNA-binding proteins also found in stress granules.